Caudill Cortney 4
4 · HALOZYME THERAPEUTICS, INC. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Halozyme (HALO) COO Cortney Caudill Receives 44,248-Share Award
What Happened Cortney Caudill, Chief Operating Officer of Halozyme Therapeutics (HALO), was granted four derivative equity awards on February 9, 2026 totaling 44,248 units (14,047; 13,047; 2,403; 14,751). Each grant is reported at $0.00 (derivative awards/awarded stock units), meaning no cash was paid at grant; the awards are subject to vesting and/or performance conditions described in the filing. This is an award/grant (not a purchase or sale) and does not by itself signal an immediate market transaction.
Key Details
- Transaction date: 2026-02-09; reported on Form 4 filed 2026-02-11 (timely filing).
- Grants reported (all "A" = award/acquisition, derivative, $0.00): 14,047; 13,047; 2,403; 14,751 — total 44,248 units.
- Shares owned after the transaction: not disclosed in the excerpt provided (check the full Form 4 for total holdings).
- Notable footnotes from the filing:
- F1: An option award with vesting of one-fourth on the indicated date and then 1/48th monthly thereafter.
- F2: A time-based award vesting one-fourth on the first anniversary, then one-fourth on each subsequent anniversary.
- F3: PSUs from 2/23/2024 — the listed units reflect the number that became eligible to vest based on performance for the period ending 12/31/2025; units remain subject to a service requirement through the third anniversary of the PSU grant date.
- F4: PSUs from 2/20/2025 — similarly, these reflect performance-determined units for period ending 12/31/2025 and remain subject to a service-based vesting requirement through the third anniversary of the grant.
- Filing timeliness: Form 4 was filed within the standard SEC two-business-day window (transaction 2/9/2026, filed 2/11/2026).
Context These entries are derivative equity awards (stock options, time-based RSUs, and performance-based RSUs/PSUs) and generally represent future economic interest contingent on vesting or achievement of performance goals and service requirements. They are not cash purchases or sales and do not indicate immediate buying/selling activity. For full details on total holdings, exact vesting dates, and potential future dilution or realized value, consult the complete Form 4 filing and Halozyme’s grant agreements.
Insider Transaction Report
- Award
Option to Purchase Common Stock
[F1]2026-02-09+14,047→ 14,047 totalExercise: $80.48From: 2027-02-09Exp: 2036-02-09→ Common Stock (14,047 underlying) - Award
Restricted Stock Units
[F2]2026-02-09+13,047→ 13,047 totalExercise: $0.00From: 2027-02-09→ Common Stock (13,047 underlying) - Award
Performance Stock Units
[F3]2026-02-09+2,403→ 13,886 totalExercise: $0.00→ Common Stock (2,403 underlying) - Award
Performance Stock Units
[F4]2026-02-09+14,751→ 14,751 totalExercise: $0.00→ Common Stock (14,751 underlying)
Footnotes (4)
- [F1]This option vests one-fourth on such date and then 1/48th monthly thereafter.
- [F2]This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
- [F3]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
- [F4]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.